Context Therapeutics Inc. announced on May 29, 2025, the appointment of Dr. Karen Chagin, M.D., as Chief Medical Officer (CMO), effective June 9, 2025. Dr. Chagin succeeds Dr. Karen Smith, who served as interim CMO and will remain a member of the company’s Board of Directors.
Dr. Chagin brings over a decade of leadership in clinical development and regulatory strategy for T cell therapies in solid tumors, with previous roles at Adaptimmune Therapeutics plc and Tmunity Therapeutics. Notably, she played a critical role in the development and approval of Tecelra, the first engineered cell therapy approved in the U.S. for a solid tumor.
Her deep experience in advancing T cell therapies from early development through approval is expected to be invaluable as Context progresses its portfolio of T cell engaging bispecific therapeutics. This appointment strengthens the company's leadership at a pivotal stage of its growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.